Eventide Asset Management Announces Promotion of Anant Goel, Joy Ghosh and Andrew Singer to Portfolio Managers



[ad_1]

BOSTON, December 10, 2021 / PRNewswire / – Eventide Asset Management is pleased to announce the promotion of Anant Goel, Joy Gosh, and Andrew singer in portfolio management roles within the company. The promotions will provide additional oversight for the positioning and strategy implementation of multiple Eventide funds in conjunction with Senior Portfolio Managers / Co-CIOs, Dr Finny Kuruvilla, MD, PhD, and Ms. Dolores Bamford, CFA. “Each of these individuals brings an impressive background as well as an intuitive understanding of Eventide’s mission and values. Adding them as portfolio managers will strengthen our strong team structure and be of great value to our shareholders.” Ms Bamford said of the promotions. .

“It’s a central part of our long-term strategy at Eventide to hire and coach uniquely talented people, and then give them leadership roles that match their gifts and background,” commented the Dr Kuruvilla. “Anant, Joy and Andrew have each proven their commitment to continuing our high level of excellence, and I am delighted to add them as portfolio managers.”

Anant Goel is promoted to Portfolio Manager of the Eventide Gilead Fund alongside Senior Portfolio Manager Finny Kuruvilla, MD, PhD. Mr. Goel is currently Portfolio Manager for Eventide Exponential Technologies Fund and Senior Research Analyst for Eventide Gilead Fund. His new position is effective January 1, 2022.

“I have long been impressed with Anant’s intuition and unique perspective on the markets, portfolio positioning and stock selection,” said Dr Kuruvilla of the Goel promotion. “He has been a tremendous asset to the Eventide Gilead Fund as a Senior Research Analyst and has proven to be an excellent leader, managing the Eventide Exponential Technologies Fund.”

Goel has been part of Eventide’s investment team as a research analyst since joining the company in 2016, leading its technology-driven research. In 2015, during his MBA program, he worked at Adage Capital Management, a long-short hedge fund. From 2011 to 2014, he was an analyst for NewQuest Capital Partners, a private equity firm in Hong Kong, where he was responsible for evaluating new investment opportunities for the funds through Asia.

Mr. Goel holds an MBA from the MIT Sloan School of Management and a Bachelor of Science (HONS) from the University of Warwick, United Kingdom, in economics.

Joy Gosh, PhD, is promoted to portfolio manager of the Eventide Healthcare & Life Sciences fund alongside lead portfolio manager Finny Kuruvilla, MD, PhD. Dr Ghosh is currently Senior Research Analyst for Eventide. His new position is effective January 1, 2022.

“Eventide’s approach within the Health and Life Sciences Fund requires the unique perspective of an individual with in-depth knowledge of both the science underlying biotechnology innovation and the markets for capital that finances its growth, ”said Dr Kuruvilla of Dr Ghosh’s promotion. “Joy brings impressive experience as a scientist and investor. His leadership as a portfolio manager should position the Fund well for many years to come.”

Dr Ghosh has an interdisciplinary background in biopharmaceutical / biotechnology R&D, business development / M&A and healthcare investment. Before joining Eventide, from 2017 to 2020, he was a partner and then vice-president at Bain Capital for their Life Sciences fund. From 2016 to 2017, he was Senior Manager at Biogen. From 2009 to 2016, he was a researcher at the Novartis Biomedical Research Institutes. Before Novartis, he was a postdoctoral researcher at Brigham and Women’s Hospital /Harvard Medical School and Boston University School of Medicine.

Dr Ghosh holds a doctorate from University of Washington, Seattle, in biomolecular structure and design and a bachelor’s degree in biochemistry from the University of Texas at Austin.

Andrew singer, CFA is promoted to portfolio manager of the Eventide Dividend Opportunities fund alongside lead portfolio manager Dolores Bamford, CFA. Mr. Singer is currently Associate Portfolio Manager of Eventide Dividend Opportunities Fund. His new position is effective January 1, 2022.

“Andrew was a thought leader and key contributor to the Eventide investment team prior to the creation of the Eventide Dividend Opportunity Fund,” Ms. Bamford said of the Singer promotion. “I relied heavily on his insight and veteran perspective on key industries, company fundamentals and valuation analysis. His promotion to the position of portfolio manager will formalize his position as a partner in the direction of the ongoing management of the Fund.

Prior to joining Eventide, Mr. Singer held investment analyst positions at Credit Suisse, BlackRock and John hancock, where he focused on small and mid cap stocks across various sectors. He holds a bachelor’s degree in quantitative economics from Tufts University and an MBA from Babson College. He holds the Chartered Financial Analyst designation and is a member of the CFA Society Boston and the CFA Institute.

Eventide Asset Management, LLC, is a Boston-investment advisor based looking for “investments that make the world happy®. “Founded in 2008, Eventide’s vision is to serve individuals, financial advisers and institutions by seeking to deliver high performing investments that they believe create compelling value for the global common good.

Mutual funds come with risks, including the possible loss of capital. Past performance is no guarantee of future results. There can be no assurance that the funds will achieve their objectives. The criteria for selecting the ethical values ​​of funds could lead them to underperform similar funds which do not have such selection criteria.

Important risk information

The Gilead Fund may invest in smaller companies, which may experience higher failure rates than larger companies and normally have lower transaction volumes than larger companies. The Fund may present a risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain results and on decisions made by the United States Food and Drug Administration. Companies in technology industries face various risks, including, but not limited to, product obsolescence and the entry of competing products. Companies in the industrial sector carry a variety of risks, including, but not limited to, the risk of indebtedness, intense competition and sensitivity to economic cycles. The Fund may present a risk associated with investing in options. There are special risks associated with investing in foreign companies, including exposure to currency fluctuations, less efficient trading markets, political instability, and different auditing and legal standards. The Fund may invest in private companies. Private investments involve various risks including, but not limited to, lack of liquidity, risk of capital commitment and valuation risk. Private companies may not be financially profitable and have an uncertain future, which puts them at additional risk.

The Eventide Healthcare & Life Sciences fund may invest in smaller companies, which may experience higher failure rates than larger companies and normally have lower transaction volume than larger companies. The Fund may present a risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain results and on decisions made by the United States Food and Drug Administration. The Fund may present a risk associated with investing in options. There are special risks associated with investing in foreign companies, including exposure to currency fluctuations, less efficient trading markets, political instability, and different auditing and legal standards. The Fund may invest in private companies. Private investments involve various risks including, but not limited to, lack of liquidity, risk of capital commitment and valuation risk. Private companies may not be financially profitable and have an uncertain future, which puts them at additional risk.

The Eventide Dividend Opportunities Fund may involve risks associated with investing in options. Utilities companies are exposed to interest rate risk and cash flow risk. Companies in technology industries face various risks, including, but not limited to, product obsolescence and the entry of competing products. Companies in the industrial sector carry a variety of risks, including, but not limited to, the risk of indebtedness, intense competition and sensitivity to economic cycles. The Fund may invest in smaller companies which may experience higher failure rates than larger companies and normally have a lower transaction volume than larger companies. There are unique risks associated with convertible securities, foreign securities, hedging, MLPs, preferred stocks, REITs, securities and yieldcos that are covered in the Fund’s prospectus and the IAS.

Investors should carefully consider the investment objectives, risks, fees and expenses of a fund before investing or sending money. This and other important information can be found in the prospectus, which can be obtained at www.eventidefunds.com or by calling 1-877-771-EVEN (3836). Please read the prospectus carefully before investing. Eventide mutual funds are distributed by Northern Lights Distributors, LLC, a member of FINRA / SIPC, which is not affiliated with Eventide Asset Management, LLC.

Close contact:
Harry nelson 877-771-SAME (3836)

7405-NLD-11122021

SOURCE Eventide Asset Management

[ad_2]

Previous Peploe's paintings sell for over £ 1million
Next 5 social security mistakes to avoid